Effect of PEmafibRate on Sympathetic nErve fUnction in hypertriglyceridemia patients with obeSity and hypertensio
Phase 4
Recruiting
- Conditions
- Obesity, Hypertension, Dyslipidemia
- Registration Number
- JPRN-UMIN000042852
- Lead Sponsor
- Department of Cardiovascular Medicine, Kyoto University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with contraindications to the target drug. 2. Patients with chronic atrial fibrillation or pacemaker implantation Patients with severe impairment of cardiovascular or pulmonary function such as shock, heart failure, myocardial infarction, pulmonary embolism, and other patients prone to hypoxemia. 4. Patients with excessive alcohol intake 5. Patients with severe infections, before and after surgery, or with severe trauma Patients with malnutrition, starvation, weakness, pituitary insufficiency, or adrenal insufficiency. 7. Other patients who are deemed inappropriate by the attending physician.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in LF/HF from baseline at 24 weeks post-treatment
- Secondary Outcome Measures
Name Time Method 1. Change in HF and LF from baseline at 24 weeks after initiation of treatment 2. Change from baseline at 24 weeks after the start of study treatment for the following 1) Change in heart rate variability index 2) Frequency of extrasystoles and arrhythmias 3) Body measurements: weight, BMI 4) Carotid artery IMT 5) Abdominal circumference, Catecholamine, General blood collection results